

H.R. 620, Alzheimer’s Accountability and Investment Act

As reported by the House Committee on Energy and Commerce on May 31, 2024

By Fiscal Year, Millions of Dollars	2024	2024-2029	2024-2034
Direct Spending (Outlays)	0	0	0
Revenues	0	0	0
Increase or Decrease (-) in the Deficit	0	0	0
Spending Subject to Appropriation (Outlays)	0	0	0
Increases <i>net direct spending</i> in any of the four consecutive 10-year periods beginning in 2035?	No	Statutory pay-as-you-go procedures apply?	No
		Mandate Effects	
Increases <i>on-budget deficits</i> in any of the four consecutive 10-year periods beginning in 2035?	No	Contains intergovernmental mandate?	No
		Contains private-sector mandate?	No

H.R. 620 would require the National Institutes of Health to prepare annual estimates of the costs of research conducted under the National Alzheimer’s Project Act. Those estimates would be submitted to the President for review and transmittal to the Congress. Because the agency already provides such information, CBO estimates that implementing H.R. 620 would have no additional effect on the federal budget.

On January 12, 2024, CBO transmitted a [cost estimate for S. 134](#), the Alzheimer’s Accountability and Investment Act, as reported by the Senate Committee on Health, Education, Labor, and Pensions on July 27, 2023. The two bills are similar, and CBO’s estimates of their budgetary effects are the same.

The CBO staff contact for this estimate is Ali Khan. The estimate was reviewed by Emily Stern, Senior Adviser for Budget Analysis.



Phillip L. Swagel
Director, Congressional Budget Office